Double Bond Pharmaceutical expands the cooperation with Alexandrov Cancer Centre to identify biomarkers for Temodex
As previously described, DBP has recently started an extensive partnership agreement with N. N. Alexandrov National Centre of Belarus on Temodex. Now the cooperation is deepened further and includes the identification of potential biomarkers for Temodex.
"Biomarkers are absolutely central in the development of modern drugs, especially as so-called personalized medicine becomes increasingly vital in the pharmaceutical world. We see a great potential and opportunities in effective development of biomarkers, - says Igor Lokot, CEO of DBP. - This ensures further the therapeutic value of Temodex on the market and substantially increases the possibility for Temodex to become part of the new standard odf care for operable brain cancer globally. "
"Purpose of this cooperation is not only to develop new biomarkers for the treatment of brain cancer. The entire scope of cooperation will gather evidence for our earlier hypothesis that Temodex also works on patients who do not normally respond well to standard systemic treatment with temozolomide" - says Iulia Karlsson, Head of Biomarker and Companion Diagnostics Development in DBP.
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15th of February 2017.
More about N.N. Alexandrov National Cancer Centre of Belarus:
N.N. Alexandrov National Cancer Centre is the leading cancer centre in Belarus. It provides the whole scope of services in the field of diagnosis and treatment of malignant tumors.
N.N. Alexandrov National Cancer Centre is also the greatest medical research institution of the Republic of Belarus. It provides free of charge examination and treatment of Belarusian citizens with malignant tumors and renders paid medical services for foreign citizens and Belarusian citizens without malignant diseases.
For more information, read here.
Temodex, which is a locally acting formulation of temozolomide, was developed by RI PCP in Minsk, Belarus, and is registered for marketing within Belarus since 2014 as the first-line treatment of glioblastoma. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. Find out more here.
For more info, contact
Igor Lokot, CEO
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. DBP acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015. The company was granted Orphan Drug Designation status by EMA for Temodex in July 2016.